QIVIGY® now available to patients in the US: a journey from concept to care

The therapy was developed, manufactured, and released through our integrated global network, reflecting more than a decade of scientific research and manufacturing investment

Kedrion’s 10% Intravenous Immunoglobulin (IVIG) therapy approved by the US Food and Drug Administration in late 2025, is now available for adults living with Primary Humoral Immunodeficiency (PI) across the United States.

Kedrion has activated a robust, nationwide distribution network to support the availability of the therapy. The model provides broad access through specialty pharmacies, infusion centers, hospitals, and other care settings, ensuring consistent supply and scalable reach as demand for IVIG therapies continues to grow in the US.

The therapy was developed, manufactured, and released through Kedrion’s integrated global network, reflecting more than a decade of scientific research and manufacturing investment. This long-term commitment reinforces consistency, quality, and supply reliability.

Beyond distribution, the availability of this product aligns with Kedrion’s fully integrated international manufacturing strategy aimed at improving access to high‑quality plasma‑derived therapies worldwide. This approach strengthens supply reliability for both healthcare providers and the patients we serve.